Pentoxifylline-d6
(Synonyms: 己酮可可碱 d6) 目录号 : GC48829
An internal standard for the quantification of pentoxifylline
Cas No.:1185879-03-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pentoxifylline-d6 is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent.1 It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 µM.2 Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood.3 It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg/kg.4 Formulations containing pentoxifylline have been used in the treatment of intermittent claudication.
1.Ward, A., and Clissold, S.P.Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacyDrugs34(1)50-97(1987) 2.S?oczyńska, K., KÓzka, M., P?kala, E., et al.In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous diseaseActa Biochim. Pol.60(1)129-135(2013) 3.Magnusson, B., Gunnarsson, M., Berntorp, E., et al.Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humansEur. J. Pharmacol.581(3)290-295(2008) 4.Michal, M., Giessinger, N., and SchrÖer, R.Reduced thrombus formation in vivo after administration of pentoxifylline (Trental)Thromb. Res.56(3)359-368(1989)
| Cas No. | 1185879-03-1 | SDF | |
| 别名 | 己酮可可碱 d6 | ||
| Canonical SMILES | O=C1C2=C(N=CN2C([2H])([2H])[2H])N(C(N1CCCCC(C)=O)=O)C([2H])([2H])[2H] | ||
| 分子式 | C13H12D6N4O3 | 分子量 | 284.3 |
| 溶解度 | Acetonitrile: soluble,DMSO: soluble,Methanol: soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5174 mL | 17.5871 mL | 35.1741 mL |
| 5 mM | 0.7035 mL | 3.5174 mL | 7.0348 mL |
| 10 mM | 0.3517 mL | 1.7587 mL | 3.5174 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。